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Summary 
Cancer contributes significantly to the burden of illness in the Australian community. Bowel 
cancer is one of the most significant cancer types in terms of incidence and mortality. In 2010, 
14,860 people were diagnosed with bowel cancer and in 2011 there were 3,999 deaths from 
the disease. Screening for bowel cancer is available in Australia through the National Bowel 
Cancer Screening Program (NBCSP), which aims to reduce the incidence, illness and 
mortality related to bowel cancer through screening to detect cancers and pre-cancerous 
lesions in their early stages, when treatment is most successful. 
Reporting statistics about the NBCSP in a standardised way is vital to ensure that 
governments, researchers and health workers have access to relevant and reliable statistics 
about the performance of the program over time. This report describes the National Bowel 
Cancer Screening Program Performance Indicator Set (NBCSP PIs) and is a reference tool for 
anyone who wishes to understand, measure and report the progress of bowel cancer 
screening in Australia. 
The indicators were developed by the National Bowel Cancer Screening Program Report and 
Indicator Working Group (the working group) and have been endorsed by the Standing 
Committee on Screening, the Community Care and Population Health Principal Committee, 
the National Health Information Standards and Statistics Committee and the National 
Health Information and Performance Principal Committee. The indicators are consistent 
with the five Australian Population Based Screening Framework (PBSF) steps of recruitment, 
screening, assessment, diagnosis and outcomes. 
This report outlines both the development process and the technical specification for the  
11 agreed indicators that are part of the NBCSP PIs. This report also identifies data sources 
and any future data development.  
Table S.1: NBCSP performance indicators 
PBSF step PBSF aim NBCSP performance indicator 
Recruitment Targeted population encouraged to 
participate in screening 
01—Participation rate  
Screening Targeted population who participate 
in screening 
02—Screening positivity rate 
Assessment Screened population who require 
further assessment 
03—Diagnostic assessment rate 
04—Time between positive screen and diagnostic assessment  
Diagnosis Assessed participants diagnosed 
with the condition 
05a—Adenoma detection rate  
05b—The positive predictive value of diagnostic assessment for 
detecting adenoma   
06a—Colorectal cancer detection rate  
06b—The positive predictive value of diagnostic assessment for 
detecting colorectal cancer 
07—Interval cancer rate  
08—Cancer clinic-pathological stage distribution  
Outcomes Reduced morbidity and mortality 
from the condition 
09—Adverse events—hospital admission  
10—Incidence of colorectal cancer 
11—Mortality from colorectal cancer  
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1 Introduction 
The NBCSP aims to reduce the morbidity and mortality from bowel cancer by actively 
recruiting and screening the target population for early detection or prevention of the 
disease. This report describes the key performance indicators for the National Bowel Cancer 
Screening Program (NBCSP) and is designed to be used as a reference tool by anyone who 
wishes to report on the performance of the NBCSP in Australia.  
Measuring performance through indicators 
Box 1.1: What is an indicator? 
An indicator is a statistic that can describe a situation concisely, help assess progress and 
performance, and act as a guide to decision making. 
Indicators (see Box 1.1) are important health surveillance tools that are used to establish 
points of reference, monitor the health of populations, and evaluate the outcomes of 
treatments, health service use, interventions and health programs (AIHW 2008a). 
It is important to note that, although an indicator does not provide the entire picture, it can 
indicate change. For example, a drop in rates of deaths from selected chronic diseases may 
not necessarily mean that these diseases are becoming less prevalent, but it may mean that 
treatments have improved or new treatments have been developed that extend the lives of 
those with the conditions. 
More often than not, indicators are grouped within sets, and may be specific to a committee, 
a disease of interest, a population group or a concept to be measured. For example, the 
National Health Performance Committee manages a suite of indicators that are used to 
report on health sector performance (NHPC 2004). Similarly, the Australian Institute of 
Health and Welfare (AIHW) was involved in the development of the key indicators of 
progress for chronic disease and associated determinants (AIHW 2009), the national 
indicators for monitoring diabetes (AIHW 2007) and the key national indicators of children’s 
health, development and wellbeing (AIHW 2008b). 
The National Bowel Cancer Screening Program 
Cancer contributes significantly to the burden of illness in the Australian community. Of the 
many types of cancer, bowel cancer is one of the most significant in terms of incidence and 
mortality. In 2010, 14,860 people were diagnosed with bowel cancer and in 2011 there were 
3,999 deaths from bowel cancer—9% of all deaths from invasive cancers, and second only to 
lung cancer.  
Screening for bowel cancer is available in Australia through the NBCSP, which aims to 
reduce the morbidity and mortality associated with bowel cancer (see Box 1.2 for NBCSP 
goals and objectives). The NBCSP, implemented in 2006, currently offers free bowel cancer 
screening using a faecal occult blood test kit (FOBT) to people turning 50, 55, 60 and 65 years 
of age. The program is scheduled to be expanded from July 2015, with phasing in of biennial 
screening for those aged 50 to 74 by 2020.  
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Box 1.2: NBCSP goal and objectives 
Goal 
To reduce the morbidity and mortality from bowel cancer by actively recruiting and 
screening the target population for early detection or prevention of the disease. 
Objectives 
1. To achieve participation levels that maximise the population benefit of early detection 
of bowel cancer in the target population.  
2. To enable equitable access to the program for men and women in the target population, 
irrespective of their geographic, socioeconomic, disability or cultural background, to 
achieve patterns of participation that mirror the general population. 
3. To facilitate the provision of timely, appropriate, high quality and safe diagnostic 
assessment services for program participants.   
4. To maximise the benefits and minimise harm to individuals participating in the 
program.   
5. To ensure the program is cost effective and maintains high standards of program 
management and accountability.   
6. To collect and analyse data to monitor participant outcomes and evaluate program 
effectiveness. 
Source: National Bowel Cancer Screening Program Policy Framework Phase Three, July 2013-June 2017. 
Endorsed by the Community Care and Population Health Principal Committee 30 May 2013. 
The FOBT screening kit, mailed to invitees when they reach a target age, enables participants 
to take two separate screening samples, which are then mailed to the program’s pathology 
laboratory for testing. The pathologist classifies an FOBT as positive if blood is detected in a 
sample, because the presence of blood generally indicates a potential bowel abnormality, 
including cancer and pre-cancerous changes, which requires further investigation. 
Participants who have a positive FOBT test are recommended to have a colonoscopy to 
identify the source of the bleeding. Data on invitations sent, and invitees’ progression 
through the screening pathway, are recorded in a central NBCSP register.  
To allow optimal performance monitoring and evaluation of programs such as the NBCSP, it 
is vital that governments, researchers and health workers have access to up-to-date, 
standardised and relevant program statistics. These are used to develop a baseline of 
evidence and subsequently enable the monitoring of change in the screening environment 
for the population as a whole, and in population subgroups. 
Development of NBCSP performance indicators 
The NBCSP data items and measures agreed by the Implementation Advisory Group in 2006 
for phase one (2006–2008) have been used as the basis for the AIHW’s NBCSP monitoring 
reports since 2006; however, these were never formalised. The NBCSP phase two review 
(2011) recommended that key performance indicators be developed to enhance program 
monitoring and transparency. The Department of Health contracted the AIHW under its 
policy renewal process to develop formal performance indicators that were consistent with 
the Population Based Screening Framework (AHMAC 2008). 
The NBCSP performance indicator development process was undertaken by the working 
group (See list of members in Appendix D). 
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Initial review 
As a first step, the working group reviewed a number of existing frameworks and 
performance indicators, including: 
• the National Health Performance Framework (NHPC 2009) 
• the Population Based Screening Framework (AHMAC 2008) 
• indicators used for existing Australian cancer screening programs 
• the report on the development of a NBCSP Quality Framework (DLA Phillip Fox 2010) 
• the Improving Colonoscopy Services in Australia report from the NBCSP Quality Working 
Group (NBCSP-QWG 2009) 
• international colorectal cancer screening indicator sets, after contextualising to the 
Australian environment. 
Defining the scope and purpose 
Following a review of existing frameworks and performance indicators, the working group 
defined that the NBCSP performance indicators would: 
• be used by the Department of Health to inform on NBCSP performance and to assist 
future program planning and policy 
• be consistent with the Population Based Screening Framework (see Box 1.3) 
• incorporate flexibility to allow for future changes to the program 
• be designed, where possible, to allow comparison with other international performance 
indicators 
• not include an indicator on the cost-effectiveness of the program, or the consumer 
experience 
• not include continuous quality improvement steps or measures 
• not include targets (for example, a target participation rate). 
Box 1.3: The Australian Population Based Screening Framework stages  
Recruitment: Targeted population encouraged to participate in screening 
Screening: Targeted population who participate in screening 
Assessment: Screened population who require further assessment 
Diagnosis: Assessed participants diagnosed with the condition 
Outcomes: Reduced morbidity and mortality from the condition 
Source: AHMAC 2008. 
Literature review 
The working group conducted a literature review to identify international colorectal cancer 
screening initiatives. A list of 53 colorectal cancer screening indicator sources were 
examined, including indicator sets from the International Colorectal Cancer Screening 
Network (ICRCSN), the European Commission, the United Kingdom, Scotland, Canada, 
Italy, Wales, New Zealand, France and Finland. Performance indicators for Australia’s 
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National Cervical Screening Program and BreastScreen Australia and the Improving 
Colonoscopy Services in Australia (NBCSP-QWG 2009) report were also reviewed. 
The review identified that the ICRCSN would like to create a set of internationally 
comparable performance indicators for colorectal cancer screening. The working group 
agreed to use the ICRCSN’s suggested colorectal cancer screening indicators as a starting 
point for indicator development, and that the NBCSP indicators should be aligned, where 
possible, with those used by other countries (Benson et al. 2012; European Commission et al. 
2010; Scottish Bowel Screening Programme 2012; Department of Health 2005; Blanks & Moss 
2012; Zorzi et al. 2007; Bowel Screening Wales 2011; Goulard et al. 2008; Moss et al. 2012; 
Malila et al. 2011). 
Reviewing existing performance indicators 
The existing Australian and international indicator sets were reviewed to identify a list of 
potentially suitable performance indicators, given the Australian context. About 
60 performance indicators were regarded as potentially suitable for inclusion. The review 
involved describing each indicator’s attributes, investigating which international colorectal 
cancer screening initiatives used the indicator and assessing (where possible) how the 
indicator was performing where it was used. Each proposed indicator was considered based 
on its appropriateness for the Australian context, usability, collectability and duplication. See 
Appendix B for the full list of the indicators considered for the NBCSP performance indicator 
set. From this list, the working group developed 11 indicators that would be appropriate for 
measuring the performance of the NBCSP at the national level.  
Consultation and endorsement 
The proposed performance indicators were reviewed by the NBCSP Program Delivery 
Advisory Group and Clinical Advisory Group. They were then endorsed by the Standing 
Committee on Screening (SCoS) in 2013 and the Community Care and Population Health 
Principal Committee (CCPHPC) under the auspice of the Australian Health Ministers’ 
Advisory Council (AHMAC) in 2014.  
After endorsement of the performance indicators by the CCPHPC, they—along with the 
required data elements to create and analyse the indicators—were published on the 
Metadata Online Registry (METeOR). METeOR is Australia’s online repository for national 
metadata standards for health, housing and community services statistics and information. 
The METeOR items were further endorsed by both the National Health Information 
Standards and Statistics Committee and the National Health Information and Performance 
Principal Committee in 2014—steps outlined in Creating nationally-consistent health 
information: engaging with the national health information committees (AIHW 2010). 
Data limitations 
The NBCSP indicators aim to provide a comprehensive picture of the performance of the 
NBCSP in Australia, and were designed with the future in mind. Some indicators are 
aspirational, in that there was either a lack of national data or a lack of completeness of data 
at the time of their creation. For some indicators, further maturity of the NBCSP, such as the 
phasing in of biennial screening, will assist with the completeness of data. 
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Indicators with available data, which could be improved with 
additional data: 
• Indicator 05a (adenoma detection rate) and 05b (the positive predictive value of diagnostic 
assessment for detecting adenoma) could be improved by an increase in the proportion of 
forms returned for those undergoing diagnostic assessment. Further, adenoma 
information could be collected by jurisdictional cancer registries (for example, bowel 
cancer behaviours of ‘benign’ or ‘in situ’), and this could potentially be used to confirm, 
or enhance, diagnostic assessment form data. 
• Indicator 06a (colorectal cancer detection rate) and Indicator 06b (the positive predictive value of 
diagnostic assessment for detecting colorectal cancer) could be improved by an increase in the 
proportion of forms returned for those undergoing diagnostic assessment. Further, data 
availability could be improved by linking NBCSP records to the Australian Cancer 
Database (ACD). At present, the currency of ACD reporting data is generally behind the 
NBCSP reporting period and therefore reporting using ACD data, if possible, would 
affect the NBCSP period being reported.  
• Indicator 07 (interval cancer rate) requires linkage of NBCSP records to the ACD. However, 
at present the ACD reporting period is generally behind the NBCSP reporting period 
and therefore the NBCSP interval cancer rate time period reported is affected by the 
currency of the ACD data.  
• Indicator 09 (adverse events—hospital admission) may require linkage with hospital data. 
The NBCSP Register as a data source for adverse events has limitations, but it could be 
used until a more complete data source becomes available. 
Indicators with no available data that require data development: 
• Indicator 08 (cancer clinico-pathological stage distribution) requires linkage with either the 
jurisdictional cancer registries or the ACD. However, not all cancer registries currently 
record bowel cancer staging data. Where stage is recorded, not all jurisdictions have 
complete data and staging systems vary. 
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2 Indicators 
Overview of the performance indicators 
The NBCSP PI set comprises the 11 endorsed indicators used for monitoring the NBCSP 
(Table 2.1). They may also be of interest to a wider range of health and health-related 
professionals who collect and/or use the data in relation to the NBCSP.  
The NBCSP PIs provide concise, unambiguous definitions for items related to NBCSP 
reporting.  
Table 2.1: NBCSP performance indicators 
PBSF step(a) No. Program performance indicator Related NBCSP objectives(b) 
Recruitment 01 Participation rate  O2, O5, O6 
Screening 02 Screening positivity rate O1, O4, O5 
Assessment 03 Diagnostic assessment rate O2, O3, O4 
Assessment 04 Time between positive screen and diagnostic assessment  O2, O3, O4 
Diagnosis 05a Adenoma detection rate  O1, O4 
Diagnosis 05b The positive predictive value of diagnostic assessment for detecting  
adenoma   
O1, O4 
Diagnosis 06a Colorectal cancer detection rate  O1, O4 
Diagnosis 06b The positive predictive value of diagnostic assessment for detecting  
colorectal cancer 
O1, O4 
Diagnosis 07 Interval cancer rate  O1, O4 
Diagnosis 08(c) Cancer clinic-pathological stage distribution  O1, O4 
Outcomes 09(c) Adverse events—hospital admission  O3, O4 
Outcomes 10(d) Incidence of colorectal cancer O6 
Outcomes 11(d) Mortality from colorectal cancer  O6 
(a) The Australian Population Based Screening Framework stages. See Box 1.3 for more information. 
(b) See Box 1.2 for more information. 
(c) Indicators 8 and 9 are aspirational performance indicators (performance indicators where data are not currently available; however, when 
data becomes available, they would be reported). 
(d) Indicators 10 and 11 are contextual performance indicators (performance indicators not specific to the NBCSP, but provide context on the 
burden of bowel cancer in Australia, which may be related to bowel screening activity and outcomes).  
 
The NBCSP performance indicators are summarised in the following section; however, they 
can also be viewed on METeOR: 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/533361>. 
The corresponding NBCSP data set specifications for the performance indicators can be 
viewed on METeOR: <http://meteor.aihw.gov.au/content/index.phtml/itemId/529201>. 
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PI 01—Participation rate 
Table 2.2: PI 01—Participation rate 
Indicator details  
Description The percentage of people invited to screen through the NBCSP in a 24-month period who returned a 
completed screening test within the defined 24-month period or the following 6 months.  
Rationale The participation rate is a key indicator that measures the proportion of those invited who participate in 
the program. Without participation, the NBCSP cannot achieve earlier detection. The program should 
therefore monitor participation to ensure acceptability, equity and uptake, with the aim that reductions 
in incidence, morbidity and mortality can be achieved.  
Participation is the number of people screened, not the number of tests completed and is divided by 
the number of people invited.  
National Health and Medical Research Council guidelines recommend a two-yearly screening interval 
for colorectal cancer screening in Australia (ACN 2005), and a rollout for this is currently underway. 
Accordingly, this participation indicator counts participation activity over a 24-month period and uses a 
6-month follow-up period to ensure those invited have had time to respond.  
Although it would be ideal to adjust for people who do not screen because they participate in other 
forms of screening or surveillance, this is not currently possible due to restrictions in the data available. 
However, people who opt off or suspend from the program without completing the test will not be 
counted.  
Computation 100 x (numerator ÷ denominator) 
Numerator The number of people invited to screen through the NBCSP in a 24-month period who returned a 
completed screening test within the defined 24-month period or the following 6 months.  
Denominator The number of people invited in a defined 24-month period, excluding those who either opted off or 
suspended without completing a screening test.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening invitation round  
• screening test type.  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program   
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening invitation rounds are classified as ‘first’, ‘second’ or ‘third and subsequent’. 
Screening test type could include FOBT or other future screening tests, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 02—Screening positivity rate 
Table 2.3: PI 02—Screening positivity rate 
Indicator details  
Description The percentage of people who returned a valid NBCSP screening test and received a positive 
screening result (warranting further assessment) in a defined 12-month period. 
Rationale The positive screening test rate determines the diagnostic assessment workload and lesion detection 
rate. It is important that the accepted positivity range is reviewed, revised if necessary, and defensible.  
Monitoring this is useful for program planning and quality assurance. Further, monitoring the positivity 
rate by various stratifications may reveal emerging positive or negative trends that need to be 
investigated, and rectified if necessary.  
As a measure of program performance, the screening positivity is presented for a defined 12-month 
period. To ensure the latest screening results are being monitored, this indicator counts all tests 
analysed in the defined period, not tests from those invited in the defined period; therefore, the cohort 
monitored is different from that in the participation indicator.  
Computation 100 x (numerator ÷ denominator) 
Numerator The number of people who returned a valid NBCSP screening test and received a positive screening 
result in a defined 12-month period.  
Denominator The number of people who retuned a valid screening test for analysis in the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• screening test type.  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: A valid screening test is one that was able to be analysed to return either a positive or negative result. 
Inconclusive screening tests are not included. 
Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Screening test type could include FOBT or other future screening tests, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 03—Diagnostic assessment rate 
Table 2.4: PI 03—Diagnostic assessment rate 
Indicator details  
Description The percentage of people who returned a positive NBCSP screening test in a 12-month period, and 
had a follow-up diagnostic assessment, measured 12 months after the defined period.  
Rationale The appropriate movement of people from participation to diagnostic assessment is a key indicator of 
the efficiency and the impact of the program in reducing morbidity and mortality from colorectal cancer.  
While not all participants with a positive screen will necessarily undergo assessment, according to the 
Population Based Screening Framework (AHMAC 2008), systems should be in place to ensure timely 
follow-up to diagnostic assessment for individuals with a positive screening test.  
Assessment services should be managed in a way that provides equity of access to the relevant 
assessment services regardless of geographic location, ethnicity or socioeconomic status. Annual 
monitoring of the diagnostic assessment rate by various stratifications may reveal emerging positive or 
negative trends that need to be investigated and rectified if necessary.  
To reduce the effect of any time lag between invitation, positive screen and diagnostic assessment, 
this indicator includes all those with a positive screen in the defined period, not all those invited in the 
defined period.  
Computation 100 x (numerator ÷ denominator) 
Numerator The number of people who received a positive NBCSP screen in a defined 12-month period and had a 
follow-up diagnostic assessment within the defined period or the following 12 months.  
Denominator The number of people who received a positive screen in the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• diagnostic assessment type  
• patient hospital election status (public or private). 
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 04—Time between positive screen and diagnostic 
assessment 
Table 2.5: PI 04—Time between positive screen and diagnostic assessment 
Indicator details  
Description For those who received a positive NBCSP screening test (warranting further assessment) in a defined 
12-month period, the time interval between the positive screening test and a follow-up diagnostic 
assessment, measured as median, 90th percentile, and participant diagnostic assessments within 
certain time cut offs, measured 12 months after the defined period.  
Rationale Waiting for a definitive diagnosis following a positive screen can create anxiety.  
There are various steps, participant decisions and wait times in the pathway between a positive screen 
and a diagnostic assessment. Therefore, this indicator should not be considered a hospital wait time 
indicator. However, after a positive screen, further diagnostic evaluation should occur in a timely 
fashion as there is a defined risk of colorectal cancer in those with a positive screening test—and any 
harms (such as anxiety) from a positive screen should be minimised.  
Numerator All NBCSP participants who received a positive screen in a defined 12-month period who underwent 
diagnostic assessment within 12 months of the defined period.  
For all people who underwent a diagnostic assessment after a positive screen in a 12-month period (as 
measured 12 months after the period to be reported):  
• The median and 90th percentile value (in days) between the date the positive screen result 
was sent to the participant and the subsequent diagnostic assessment date  
• The number of participants for whom the time between the date of the positive screen result 
and diagnostic assessment was less than or equal to 30 days, less than or equal to 60 days, 
less than or equal to 90 days, less than or equal to 180 days, less than or equal to 360 days 
or greater than 360 days.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• diagnostic assessment type  
• patient hospital election status (public or private).   
Some disaggregations may result in numbers too small for publication. 
Unit of measure Time (e.g. days, hours) 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 05a—Adenoma detection rate 
Table 2.6: PI 05a—Adenoma detection rate 
Indicator details  
Description The proportion of people who returned a valid NBCSP screening test in a defined 12-month period 
who were diagnosed with an adenoma within the defined period or the following 12 months.  
Rationale Adenomas are benign growths that have the potential to become cancerous, and their removal is likely 
to lower the risk of future colorectal cancer. Therefore, the adenoma detection rate (particularly the 
detection of advanced adenomas) is one measure of the effectiveness of the program.  
This indicator is defined to calculate the proportion of people who screened and had an adenoma 
detected, not the number of adenomas found per 100 diagnostic assessments. Therefore, it should not 
be used as a measure of the quality of diagnostic assessment.  
To reduce the effect of any time lag between invitation, positive screen, diagnostic assessment and 
histopathology, this indicator includes all those who screened in the defined period, not all those 
invited in the defined period (who had a positive screen).  
Computation 10,000 x (numerator ÷ denominator) 
Numerator The number of people who returned a valid NBCSP screening test in a defined 12-month period who 
were diagnosed with an adenoma within the defined period or the following 12 months.  
Denominator The number of people who returned a valid screening test for analysis in the defined 12-month period. 
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• screening test type  
• diagnostic assessment type  
• patient hospital election status (public or private)    
• colorectal polyp(s) type.  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Screening test type could include FOBT or other future screening tests, as data becomes available. 
Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
Colorectal polyp(s) type includes advanced adenoma and non-advanced adenoma. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
 12 Key performance indicators for the National Bowel Cancer Screening Program 
PI 05b—Positive predictive value of diagnostic 
assessment for detecting adenoma 
Table 2.7: PI 05b—Positive predictive value of diagnostic assessment for detecting adenoma 
Indicator details  
Description The percentage of people who returned a positive NBCSP screening test (warranting further 
assessment) that underwent a diagnostic assessment and were diagnosed with an adenoma, 
measured 12 months after the defined period.  
Rationale The NBCSP aims to maximise the early detection of colorectal cancer in the target population. 
Adenomas are benign growths that have the potential to become cancerous, and their removal is likely 
to lower the risk of future colorectal cancer in these patients.  
This indicator calculates the positive predictive value of follow-up assessment for detecting adenomas. 
This is a measure of the quality and effectiveness of diagnostic assessment for detecting serious 
colorectal abnormality.  
Monitoring the positive predictive value of diagnostic assessment for detecting adenoma by various 
stratifications may also reveal emerging positive or negative trends that need to be investigated and 
rectified if necessary.  
To reduce the effect of any time lag between invitation, positive screen, diagnostic assessment and 
histopathology, this indicator includes all those who underwent diagnostic assessment in the defined 
period, not all those invited in the defined period (who had undergone diagnostic assessment).  
Computation 100 x (numerator ÷ denominator) 
Numerator The number of people who returned a positive NBCSP screening test that underwent a diagnostic 
assessment and were diagnosed with an adenoma within a defined 12-month period or the following 
12 months.  
Denominator The number of people who underwent diagnostic assessment to follow up a positive screening test in 
the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• diagnostic assessment type  
• patient hospital election status (public or private)  
• colorectal polyp(s) type.  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
Colorectal polyp(s) type includes advanced adenoma and non-advanced adenoma. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 06a—Colorectal cancer detection rate 
Table 2.8: PI 06a—Colorectal cancer detection rate 
Indicator details  
Description The proportion of people who returned a valid NBCSP screening test in a 12-month period and were 
diagnosed with a screen-detected colorectal cancer, measured 12 months after the defined period.  
Rationale The NBCSP aims to maximise the early detection of colorectal cancer in the target population.  
This can be achieved by detecting cases of colorectal cancer before a person has symptoms, enabling 
early intervention. The cancer detection rate is a key indicator of program effectiveness, especially 
when comparing this rate to the known colorectal cancer incidence rate in the target population. 
Monitoring the cancer detection rate by various stratifications may also reveal emerging positive or 
negative trends that need to be investigated and rectified if necessary.  
To reduce the effect of any time lag between invitation, positive screen, diagnostic assessment and 
histopathology, this indicator includes all those who screened in the defined period, not all those 
invited in the defined period (who had a positive screen).  
Computation 10,000 x (numerator ÷ denominator) 
Numerator The number of people who returned a valid NBCSP screening test in a defined 12-month period who 
were diagnosed with a screen-detected colorectal cancer within the defined period or the following 
12 months.  
Denominator The number of people who returned a valid screening test for analysis in the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• diagnostic assessment type  
• patient hospital election status (public or private).    
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 06b—Positive predictive value of diagnostic 
assessment for detecting colorectal cancer 
Table 2.9: PI 06b—Positive predictive value of diagnostic assessment for detecting colorectal cancer 
Indicator details  
Description The percentage of people who returned a positive NBCSP screening test (warranting further 
assessment) that underwent a diagnostic assessment and were diagnosed with cancer, measured 12 
months after the defined period.  
Rationale This indicator calculates the positive predictive value of follow-up assessment for detecting cancers. 
This is a measure of the quality and effectiveness of diagnostic assessment.  
The NBCSP aims to maximise the early detection of colorectal cancer in the target population.  
This can be achieved by detecting cases of colorectal cancer before a person has symptoms, enabling 
early intervention.  
Monitoring the cancer detection rate by various stratifications may also reveal emerging positive or 
negative trends that need to be investigated and rectified if necessary.  
To reduce the effect of any time lag between invitation, positive screen, diagnostic assessment and 
histopathology, this indicator includes all those who underwent diagnostic assessment in the defined 
period, not all those invited in the defined period (who had undergone diagnostic assessment).  
Computation 100 x (numerator ÷ denominator) 
Numerator The number of people who returned a positive NBCSP screening test that had a diagnostic 
assessment and were diagnosed with screen-detected cancer in a defined 12-month period or the 
following 12 months.  
Denominator The number of people who underwent diagnostic assessment to follow up a positive screening test in 
the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• diagnostic assessment type  
• patient hospital election status (public or private).    
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 07—Interval cancer rate 
Table 2.10: PI 07—Interval cancer rate 
Indicator details  
Description The proportion of people who returned a NBCSP screening test in a defined 12-month period who 
were diagnosed with colorectal cancer (not involving a positive NBCSP screen and positive 
assessment) in the following 24-month period, or before their next screen, whichever comes first.  
Rationale An interval cancer is a colorectal cancer that is diagnosed after a screen that detected no cancer and 
before the next screen or in the following 24 months, whichever is earlier. Interval cancers are 
inevitable in a population based screening program; a low interval cancer rate is desirable.  
A high interval cancer rate reduces the potential for the program to achieve reductions in morbidity and 
mortality from colorectal cancer. Monitoring interval cancer rates is also important to assess the 
diagnostic assessment component of the screening pathway.  
Monitoring the interval cancer rate by various stratifications may also reveal emerging positive or 
negative trends that need to be investigated and rectified if necessary.  
Computation 10,000 x (numerator ÷ denominator) 
Numerator The number of people who returned an NBCSP screening test in a defined 12-month period who were 
diagnosed with colorectal cancer in the following 24 months (or before their next screen), after 
negative or inconclusive screen(s), or a positive screen and negative assessment(s).  
Denominator The number of people who returned a negative screening test or a positive screening test with a 
negative diagnostic assessment in the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round  
• screening test type  
• screening test result and colorectal polyp(s) found indicator.  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Screening test type could include FOBT or other future screening tests, as data becomes available. 
Screening test result and colorectal polyp(s) found is disaggregated by negative screen, or positive 
screen result and negative diagnostic assessment screening outcomes. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 08—Cancer clinico-pathological stage distribution 
Table 2.11: PI 08—Cancer clinico-pathological stage distribution 
Indicator details  
Description The percentage of people who had received a NBCSP invite and were later diagnosed with colorectal 
cancer in a defined 12-month period, by clinico-pathological stage.  
Rationale A key goal of the NBCSP is to detect colorectal cancers at an earlier clinico-pathological stage than 
would otherwise have been detected if there was no organised colorectal screening program in 
Australia.  
Detecting cancer at an earlier clinico-pathological stage is associated with improved patient prognosis 
(Morris et al. 2007).  
Computation 100 x (numerator ÷ denominator) 
Numerator The number of people who had received an NBCSP invitation, and were later diagnosed with 
colorectal cancer in a defined 12-month period, by clinico-pathological stage (either Stage I, Stage II, 
Stage III, Stage IV, Stage unknown or Inadequately staged).  
Denominator The number of people who were diagnosed with colorectal cancer in the defined 12-month period that 
had received a NBCSP invitation.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• disease screening round (for those who screened) 
• screening test type 
• diagnostic assessment type  
• screen-detected/Interval/did not screen. 
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Additional clinico-pathological stage data required. See Data limitations. 
Comments: Disease screening rounds are classified as ‘first screen’ or ‘subsequent screens’, where subsequent is 
disaggregated into greater than 2 years and less than or equal to 2 years after previous screen. 
Screening test type could include FOBT or other future screening tests, as data becomes available. 
Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
Screen-detected refers to cancers diagnosed after a positive screen. Interval-detected cancers refer to 
cancer diagnosed after a negative screen. Did not screen refers to cancers diagnosed in those who did 
not screen (within 2 years) after their last invitation. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 09—Adverse events (hospital admission rate) 
Table 2.12: PI 09—Adverse events (hospital admission rate) 
Indicator details  
Description The rate at which people who had a diagnostic assessment in a defined 12-month period were 
admitted to hospital within 30 days of the assessment, measured 6 months after the defined period.  
Rationale As with any invasive procedure, there is the risk of an adverse event occurring with a colonoscopy or 
other diagnostic assessment.  
Maximising benefit and minimising harm is an important tenet of population screening. Accordingly, it is 
important to report the known harms from screening when monitoring the performance of the program. 
Further, many international colorectal screening programs report this indicator, which would bring 
Australian monitoring in line with International programs and allow comparisons to be computed if 
required.  
To operationalise the monitoring of adverse events, the rate at which people who had a diagnostic 
assessment in a 12-month period were admitted to hospital within 30 days of that procedure should be 
monitored.  
To reduce the effect of any time lag between invitation, positive screen, and diagnostic assessment 
(with adverse event), this indicator includes all those who had a diagnostic assessment in the defined 
period, not all those invited in the defined period (who had a diagnostic assessment).  
Computation 10,000 x (numerator ÷ denominator) 
Numerator The number of people who returned a positive NBCSP screening test and had a diagnostic 
assessment in a defined 12-month period who were admitted to hospital in the next 30 days.  
Denominator The number of people who returned a positive NBCSP screening test and had a diagnostic 
assessment in the defined 12-month period.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
• main language spoken at home  
• disability status  
• diagnostic assessment type  
• patient hospital election status (public or private).    
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source National Bowel Cancer Screening Program  
Frequency: 6-monthly (register snapshot)  
Data custodian: Medicare Australia  
Additional source of hospital admission data may be required. See Data limitations. 
Comments: Diagnostic assessment type could include colonoscopy, CT colonography or other appropriate 
investigation, as data becomes available. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 10—Colorectal cancer incidence rate 
Table 2.13: PI 10—Colorectal cancer incidence rate 
Indicator details  
Description The incidence rate of colorectal cancer per 100,000 estimated resident population in a 12-month 
period.  
Rationale Incidence data provide contextual information about the number of new cases of colorectal cancer in 
the population which can inform National Bowel Cancer Screening Program (NBCSP) planning.  
Computation 100,000 x (numerator ÷ denominator) 
Numerator The number of new cases of colorectal cancer in a 12-month period.  
Denominator Australian estimated resident population.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status.  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source Australian Cancer Database  
Frequency: Annual 
Data custodian: Australian Institute of Health and Welfare  
 
ABS Estimated resident population (total population)  
Frequency: Quarterly 
Data custodian: Australian Bureau of Statistics  
 
ABS Indigenous experimental estimates and projections (2001 Census-based) 
Frequency: Periodic  
Data custodian: Australian Bureau of Statistics  
Comments: Primary, malignant ICD-10 topology codes C18–C20 are used to define colorectal cancer. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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PI 11—Colorectal cancer mortality rate 
Table 2.14: PI 11—Colorectal cancer mortality rate 
Indicator details  
Description The mortality of colorectal cancer per 100,000 estimated resident population in a 12-month period.  
Rationale Mortality data provide contextual information about trends in the level of colorectal cancer mortality in 
the population which can inform the National Bowel Cancer Screening Program (NBCSP) planning.  
Computation 100,000 x (numerator ÷ denominator) 
Numerator The number of deaths of colorectal cancer in a defined 12-month period.  
Denominator Australian estimated resident population.  
Disaggregation Items will be presented by sex and age group, by:  
• state and territory  
• socioeconomic status  
• remoteness area  
• Indigenous status  
Some disaggregations may result in numbers too small for publication. 
Unit of measure Person 
Data source AIHW National Mortality Database  
Frequency: Annual 
Data custodian: Australian Institute of Health and Welfare  
 
ABS Estimated resident population (total population)  
Frequency: Quarterly 
Data custodian: Australian Bureau of Statistics  
 
ABS Indigenous experimental estimates and projections (2001 Census-based) 
Frequency: Periodic  
Data custodian: Australian Bureau of Statistics 
Comments: Primary, malignant ICD-10 topology codes of C18–C20 are used to define colorectal cancer. 
See Appendix C for information on how disaggregations, such as remoteness area, socioeconomic 
status, Indigenous status, preferred correspondence language and disability status, are computed. 
Source: METeOR. 
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Appendix A: National Health Performance 
Committee indicator guidelines 
National Health Performance Committee indicator guidelines (NHPC 2004) state that 
indicators, when used at a program level to whole of system level, should have all or some of 
the following qualities: 
• Be worth measuring: The indicators represent an important and salient aspect of the 
public’s health or the performance of the health system. 
• Be measurable for diverse populations: The indicators are valid and reliable for the 
general population and diverse populations (that is, Aboriginal and Torres Strait 
Islander populations, sex, rural/urban and socioeconomic status). 
• Be understood by people who need to act: People who need to act on their own behalf or 
that of others should be able to readily comprehend the indicators and what can be done 
to improve health. 
• Galvanise action: The indicators are of such a nature that action can be taken at the 
national, state, local or community level by individuals, organised groups and public 
and private agencies. 
• Be relevant to policy and practice: Actions that can lead to improvement are anticipated 
and feasible—they are plausible actions that can alter the course of an indicator when 
widely applied. 
• Reflect results of actions when measured over time: If action is taken, tangible results 
will be seen indicating improvements in various aspects of the nation’s health. 
• Be feasible to collect and report: The information required for the indicator can be 
obtained at reasonable cost in relation to its value and can be collected, analysed and 
reported on in an appropriate time frame. 
• Comply with national processes of data definitions. 
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Appendix B: Reviewed indicators 
Table B.1 shows a list of the indicators reviewed by the working group. Whether the 
indicator was considered suitable for inclusion in the national performance indicator set is 
also shown. Other indicators with broad working group support, but which were not 
selected to be part of the set, are listed in Table B.2. 
Table B.1: International indicators considered by the working group, grouped into screening 
‘themes’ 
Group Indicator Suitable Indicator source(a) Indicator 
P
ar
tic
ip
at
io
n 
Number of pre-notification letters N NZ – 
Coverage rate  N ICRCSN, EC, Italy, Wales, NZ(b), 
Finland 
– 
Participation rate Y ICRCSN, EC, Scotland, Canada, 
Italy(c), Wales, France, England, 
Finland, BS Aus, NCSP 
P1 01 
Screening retention (rescreening rate) N Canada, BS Aus(d), NCSP(d) – 
Utilisation N Canada – 
Number of people ceased and suspended N Wales, NZ(e) – 
S
cr
ee
ni
ng
 
te
st
 
FOBT inadequacy rate N ICRCSN, EC, Canada
(f), Italy, 
Wales, NZ 
– 
FOBT positivity rate Y ICRCSN, Scotland, Italy, Wales, 
NZ, France, England, Finland, 
BS Aus(g), NCSP(g) 
PI 02 
G
P 
Number and rate of people who do not contact GP N Wales – 
Rate of referral to follow-up colonoscopy after positive 
test 
N EC  
Pre-assessment waits/completed N NZ – 
Did not attend GP at pre-assessment and colonoscopy N NZ – 
C
ol
on
os
co
py
 
Diagnostic/therapeutic endoscopy rate Y ICRCSN, Scotland, Canada(h), 
Italy, Wales, France, England 
PI 03 
Compliance with follow-up colonoscopy after positive 
screen 
N EC, UK, Wales – 
Adherence to follow-up N Italy – 
Rate of complete colonoscopies. Follow-up and 
screening colonoscopies to be recorded separately 
N EC, Scotland, UK, Italy, Wales – 
Rescope procedures 3, 6,12 months N Wales – 
Sedation rates N Wales – 
Proportion of polipectomies not performed during the 
diagnostic colonoscopy 
N Italy – 
   (continued) 
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Table B.1 (continued): International indicators considered by the working group, grouped into 
screening ‘themes’ 
Group Indicator Suitable Indicator source(a) Indicator 
W
ai
t t
im
e 
Wait time (from notification of positive result to 
colonoscopy) 
Y  PI 04 
Maximum time between test and receipt of result should 
be 15 days 
N EC, Italy, Wales – 
Time between invitation and laboratory receiving FOBT N Wales – 
Time between participant completing test to receipt in 
laboratory 
N Wales – 
Time between laboratory getting FOBT and result 
(laboratory turnaround) 
N Wales – 
Time between getting result and contacting GP N Wales(i) – 
Maximum time between referral after positive screening 
(any modality) and follow-up colonoscopy should be 
31 days 
N EC, Scotland(j),Canada(j), Italy(j), 
Wales(j), NZ(j) 
– 
Time interval between positive colonoscopy/FS and 
definitive management should be within 31 days 
N EC, Canada(k), Italy(k) – 
P
at
ho
lo
gy
 
Biopsies and lesions identified in the screening program 
and the subsequent resection specimen should be 
reported on a proforma 
N EC, Wales(l) – 
Rate of high-grade neoplasia reported by pathologists 
in a FOBT screening program 
N EC – 
Availability of polyps for pathological examination N UK – 
Cytology/histology correlation N BS Aus – 
O
ut
co
m
e:
 D
ia
gn
os
is
 
Cancer detection rate  Y ICRCSN, Scotland(m), UK(m), 
Canada(m),Italy(m), Wales(m), NZ, 
France, England Finland, BS 
Aus, NCSP 
PI 06a 
Polyp cancer detection rate N Scotland – 
Percentage of polyp cancers N Scotland – 
Adenoma detection rate Y ICRCSN, Scotland(n), UK(n), 
Canada, Italy(n), Wales(n), NZ, 
France, England, Finland, BS 
Aus(n) 
PI 05a 
High-risk adenoma detection rate N Scotland – 
Polyp detection rate  N ICRCSN, Wales – 
Detection rate at follow-up N Italy – 
Prevalence/incidence ratio N Italy – 
O
ut
co
m
e:
 S
ta
gi
ng
 
Percentage of people with screen detected cancers 
who are at each stage (1 for each stage level, including 
unknown) 
Y Scotland, Canada(o), Wales, 
France, England 
PI 08 
Percentage of people with screen detected cancers that 
are ‘Dukes' stage Not Known’ 
N Scotland – 
Percentage of people with screen detected cancers that 
are ‘Not staged’ 
N Scotland – 
Proportion of screen-detected cancers that are stage 
III+ (Italian) 
N Italy – 
   (continued) 
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Table B.1 (continued): International indicators considered by the working group, grouped into 
screening ‘themes’ 
Group Indicator Suitable Indicator source(a) Indicator 
O
ut
co
m
e:
 L
oc
at
io
n Percentage of people with screen detected cancers that 
are malignant neoplasms of the colon (ICD-10 C18) 
N Scotland – 
Percentage of people with screen detected cancers that 
are malignant neoplasms of the rectosigmoid junction 
(ICD-10 C19) 
N Scotland – 
Percentage of people with screen detected cancers that 
are malignant neoplasms of the rectum (ICD-10 C20) 
N Scotland – 
O
ut
co
m
e 
In
te
rv
al
 Interval CRC incidence Y Canada, Italy, Wales, France, 
BS Aus 
PI 07 
Sensitivity, program N BS Aus – 
O
ut
co
m
e:
 
A
dv
er
se
 
ev
en
ts
  
Percentage of colonoscopic complications N Scotland, UK, Canada, Italy, 
Wales, NZ, England 
– 
Mortality (all causes)(p) Y ICRCSN, Canada PI 09 
Mortality (colonoscopy-specific) N ICRCSN, Canada(q), Wales – 
O
ut
co
m
e:
 O
th
er
 Bowel cancer mortality Context  PI 11 
Bowel cancer incidence Context  PI 10 
CRC incidence, by exposure to screening N  – 
CRC mortality, by exposure to screening N  – 
Non-CRC mortality, by exposure to screening N  – 
(a)  See ‘Sources’ below for references. 
(b)  NZ coverage rate includes kits sent. 
(c)  Italy measures the inverse of participation rate; that is, measure the unreturned rate. 
(d)  BreastScreen Australia measures screening retention within 27months. Australian NCSP Screening retention includes 'early' rescreening and 
rescreening after reminder. 
(e)  NZ also measures the number of people who opt off. 
(f)  Canada excludes people who have later returned an adequate kit. 
(g)  BreastScreen Australia is a 'Recall to Assessment' rate. Australian NCSP is a cytology breakdown rate. 
(h)  Canada diagnostic endoscope rate is within 180 days of positive. 
(i)  Wales also measures the time between results and GP appointment. 
(j)  Scotland also has indicators for ‘referral to pre-assessment’, and ‘preassessment to colonoscopy’. Canada also has median and 90th 
percentile times (in days) between positive laboratory result and colonoscopies, limited to 180 days maximum. Italy has from call for 
'assessment' to 'assessment' procedure. Wales also measure time from invitation to colonoscopy. NZ had a 'time target'. 
(k)  Canada has 3 very similar indicators: ‘measure time interval for pathological diagnosis’, ‘median’ and ‘90th percentiles times’ (in days). Italy 
has time between 'assessment' and assessment result. Also, between CRC diagnosis and surgery date. 
(l)  Wales has a number of related indicators. 
(m)  Scotland has a different calculation. UK uses both 'screened' and 'colonoscopies' as denominator, plus ‘prevalent’ and ‘incident’ versions. 
Canada has all screened, all positive screens, positive screens who had colonoscopy from follow up performed within 180 days of positive. 
Canada also has versions for CRC, advanced adenoma, adenoma+CRC and advanced adenoma + CRC, with rate given 'per thousand 
screened'. Italy has FOBT for both CRC and advanced adenoma. Wales has prevalent and incident rounds.  
(n)  Scotland has a different calculation. UK uses both 'screened' and 'colonoscopies' as denominator, plus Prevalent and Incident versions. Italy 
includes 'proximal' advanced adenoma. Wales includes both adenoma and advance adenoma. BreastScreen Australia measures DCIS 
detection. 
(o)  Canada includes those with positive FOBT and colonoscopy within 180 days. 
(p)  Outcome adverse event mortality (all causes) indicators was changed to adverse events 30-day hospital admission indicator.  
(q)  Canada: the indicator is not related to CRC interventions 
Note:  ICRCSN: International Colorectal Cancer Screening Network, EC: European Commission, UK: United Kingdom, NZ: New Zealand, BS Aus: 
BreastScreen Australia, NCSP: Australia National Cervical Screening Program. 
Sources: ICRCSN: Benson et al. 2012; EC: European Commission et al. 2010; Scotland: Scottish Bowel Screening Programme 2012; UK: 
Department of Health 2005, Blanks & Moss 2012; Canada: Sourced by Graeme Young from National Colorectal Cancer Screening Network; Italy: 
Zorzi et al. 2007; Wales: Bowel Screening Wales 2011; NZ: Sourced by James St John from NZ Ministry of Health; France: Goulard et al. 2008; 
England: Moss et al. 2012; Finland: Malila et al. 2011; BS Aus: Department of Health and Ageing 2004; NCSP: AIHW 2011. 
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Table B.2: Other performance indicators with broad working group support 
Group Indicator Suitable 
Coverage/participation Up to date with screening N 
Assessment Clinical assessment (positive FOBT who see their GP/people with positive FOBT) N 
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Appendix C: Classifications 
Geographic classification 
The ability to access and provide a wide range of services is influenced by the distance 
between clients and providers, be it for the clients to travel to the service providers or for the 
providers to travel to deliver services close to a person’s home. The geographical location of 
areas is therefore an important concept in planning and analysing the provision of services.  
Geographic location is classified according to the ABS Australian Statistical Geography 
Standard (ASGS) Remoteness Structure, which groups geographic areas into six categories. 
These categories, called Remoteness Areas, are based on ASGS Statistical Area level 1 units 
and defined using the Accessibility/Remoteness Index for Australia (ARIA). ARIA is a 
measure of the remoteness of a location from the services provided by large towns or cities. 
Accessibility is judged purely on distance to 1 of the metropolitan centres. A higher ARIA 
score denotes a more remote location. The 6 Remoteness Areas are listed in Table C.1; the 
sixth, Migratory area, is not used. The category Major cities includes Australia’s capital cities, 
with the exceptions of Hobart and Darwin, which are currently classified as Inner regional. 
Further information is available on the ABS website. 
Table C.1: Remoteness areas for the Australian Statistical Geography Standard 
Region  Collection districts within region 
Major cities CDs with an average ARIA index value of 0 to 0.2 
Inner regional CDs with an average ARIA index value greater than 0.2 and less than or equal to 2.4 
Outer regional CDs with an average ARIA index value greater than 2.4 and less than or equal to 5.92 
Remote CDs with an average ARIA index value greater than 5.92 and less than or equal to 10.53 
Very remote CDs with an average ARIA index value greater than 10.53 
Migratory  Areas composed of off-shore, shipping and migratory CDs 
Residential address location of invitees (at the time of invitation) will be mapped to ASGS 
Remoteness Areas, using the most appropriate geographical unit available. 
Socioeconomic classification 
A person’s health, and their ability to access and provide a wide range of services, is also 
influenced by the relative socioeconomic advantage and disadvantage of the area in which 
they live. 
Socioeconomic classification is based on the ABS Index of Relative Socioeconomic 
Disadvantage (IRSD) for people living in different geographic areas. Geographic areas are 
assigned a score based on attributes such as low income, low educational attainment, high 
unemployment and jobs in relatively unskilled occupations. It does not refer to the 
socioeconomic situation of a particular individual, but instead refers to the area in which a 
person lives. A low score on this index means an area has more low-income families, people 
with little training and high unemployment, and may be considered disadvantaged relative 
to other areas with higher scores. However, such an area is also likely to contain some people 
who are relatively advantaged. When area-level indexes are used as proxy measures of 
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individual level socioeconomic advantage and disadvantage, many people are likely to be 
misclassified. Geographic areas may be excluded where no score is determined due to low 
populations or high levels of non-response in the underlying census.  
Residential address location of invitees (at the time of invitation) will be mapped (using a 
correspondence file) to the IRSD for that geographic area using the most appropriate 
geographical unit available. Caution should always be taken when analysing the results of 
data that have been converted using correspondences, and the potential limitations of the 
data taken into account. 
Indigenous status, main language spoken at home 
and disability status identification 
Identification of participants as Aboriginal or Torres Strait Islander, having a disability, or 
speaking a language other than English at home is by self-identification through return of a 
completed participant details form along with their completed screening test. As 
membership of these subgroups is only known for invitees who participate, it is not 
currently possible to accurately determine NBCSP participation rates (PI 01) for these 
subgroups.  
Screening test positivity cut-off 
FOBT screening test 
Currently in 2014, the Magstream HemSp using New HemTube B (Fujirebio Inc, Tokyo) 
FOBT screening test is used as the screening tool, with the positivity value set at > 20ng/mL 
haemoglobin when the sample is analysed. Each participant is asked to collect 2 samples, 
and both samples are tested individually. If either of the 2 samples are positive, the overall 
result is interpreted as positive. The expected positivity range for this test is  
4–10%, with positivity values outside of this range potentially requiring investigation. 
Adenoma definitions 
Adenoma definitions are counted on a participant level, with advanced adenomas taking 
precedence over non-advanced adenomas. For performance indicators that disaggregate by 
advanced adenoma and non-advanced adenoma, a participant with both advanced and  
non-advanced adenomas, would only be counted with the advanced adenoma—the lesion 
with the worse prognosis. Accordingly, a participant diagnosed with both an adenoma and a 
colorectal cancer would not be counted as having an adenoma, because the colorectal cancer 
would take precedence and their outcome would be recorded in the cancer-related indicators 
instead. Therefore, a count of all adenomas is a count of all people diagnosed with at least 1 
adenoma (and without a colorectal cancer), not all adenomas found. 
• Advanced adenoma: Any histopathologically confirmed adenomas that show villous 
change and/or high grade dysplasia and/or diameter of 10 mm or greater. Or a person 
with 3 or more histopathology-confirmed adenomas of any kind. 
• Non-advanced adenoma: All other confirmed adenomas not considered advanced. 
• All adenomas: Advanced and non-advanced adenomas combined. 
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Appendix D: NBCSP Report and Indicator 
Working Group members 
For the duration of the NBCSP performance indicator development work (April  
2012–current), the working group was comprised of the following members (Table D.1). 
Table D.1: National Bowel Cancer Screening Program Report and Indicator Working Group 
members 
Member Position  
Ms Mary Crum Senior Analyst, 
New South Wales Health Department 
Chair(a) 
Prof. James St John Honorary Senior Associate,  
Cancer Council Victoria  
 
Prof. Graeme Young Professor of Global Gastrointestinal Health,  
Flinders University 
 
Prof. David Hewett Gastroenterologist,  
Queensland Health 
 
Ms Kathleen O'Connor  Project Coordinator,  
Bowel Cancer Screening Implementation Team,  
Western Australia Department of Health  
 
Ms Kate Jorgenson Manager, 
Bowel Screening Section,  
Department of Health 
Chair(a) 
Ms Angela Brehaut Bowel Screening Section,  
Department of Health 
 
Ms Christine Sturrock(b) Manager, 
Cancer and Screening Unit, 
Australian Institute of Health and Welfare 
 
Mr David Meere Project Manager, 
National Bowel Cancer Screening Program 
Monitoring, 
Australian Institute of Health and Welfare 
Secretariat 
Ms Melissa Goodwin(c) Senior data analyst, 
Cancer and Screening Unit, 
Australian Institute of Health and Welfare 
 
Ms Theresa Negrello Data analyst, 
Cancer screening, 
Australian Institute of Health and Welfare 
Observer 
(a) Mary Crum resigned from her role on the working group on 8 November 2012. Kate Jorgenson took on the Chair role at that time. 
(b)  Chris Sturrock resigned from the working group on 4 June 2012. 
(c) Melissa Goodwin resigned from the working group on 1 August 2013. 
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